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Cytomegalovirus-based vaccine 
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Ebola virus infection
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Ebolaviruses pose significant public health problems due to their high lethality, unpredictable 
emergence, and localization to the poorest areas of the world. In addition to implementation of 
standard public health control procedures, a number of experimental human vaccines are being 
explored as a further means for outbreak control. Recombinant cytomegalovirus (CMV)-based vectors 
are a novel vaccine platform that have been shown to induce substantial levels of durable, but primarily 
T-cell-biased responses against the encoded heterologous target antigen. Herein, we demonstrate the 
ability of rhesus CMV (RhCMV) expressing Ebola virus (EBOV) glycoprotein (GP) to provide protective 
immunity to rhesus macaques against lethal EBOV challenge. Surprisingly, vaccination was associated 
with high levels of GP-specific antibodies, but with no detectable GP-directed cellular immunity.
Ebola virus (EBOV), a member of the family Filoviridae, is a negative, nonsegmented, single-stranded RNA 
virus responsible for zoonotic emergence of hemorrhagic fever outbreaks in humans and nonhuman primates 
(NHPs) in regions of West and Central Africa1. A recent ecological niche mapping study based on all recorded 
zoonotic EBOV transmissions from bats and NHPs to humans between the first EBOV outbreak in 1976 through 
to 2014 has identified an area at risk for EBOV zoonoses representing 22 African countries and a population of 22 
million2. In December 2013, an unprecedented EBOV outbreak starting in the West African country of Guinea 
spread to neighboring countries of Sierra Leone and Liberia resulting in the world’s largest Ebola hemorrhagic 
fever (EHF; recently also designated Ebola virus disease) epidemic3. EBOV is also highly lethal in great apes, and 
is regarded as a major threat to the survival of chimpanzees and gorillas in the wild4,5.
Vaccination can be an important component of a public health response to EBOV, especially for protection 
of healthcare workers and other individuals at high risk of infection during an ongoing EBOV outbreak in areas 
of poor infrastructure where biocontainment and contact tracing follow-up is often difficult and inadequate. 
Experience with control of other zoonoses including rabies6 and avian influenza7 also shows the potential impact 
of vaccination of intermediate host animals involved in transmission for control of zoonotic diseases such as 
EBOV.
Currently there are no licensed vaccines or therapeutic countermeasures against EBOV. However, the West 
African outbreak has focused attention on EBOV vaccine development. Over the past 15 years there has been 
remarkable progress in the development of EBOV vaccines using a variety of platforms including DNA, subu-
nit, and several viral vector approaches (replicating and non-replicating), which have shown varying degrees of 
1Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, Hamilton, Montana, United States of America. 2School of Biomedical and Healthcare 
Sciences, University of Plymouth, Devon, United Kingdom. 3Rocky Mountain Veterinary Branch, National Institute 
of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America. 
4Vaccine and Gene Therapy Institute, Oregon Health & Sciences University, Portland, Oregon, United States of 
America. 5School of Biological Sciences, University of Plymouth, Devon, United Kingdom. 6School of Medicine, 
University of California, Riverside, California, United States of America. *These authors contributed equally to this 
work. #These authors jointly supervised this work. Correspondence and requests for materials should be addressed 
to M.A.J. (email: michael.jarvis@plymouth.ac.uk)
Received: 24 September 2015
Accepted: 28 January 2016
Published: 15 February 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:21674 | DOI: 10.1038/srep21674
protective efficacy against EBOV in experimentally infected NHPs8. A number of these vaccine platforms have 
moved into clinical trials over the past year (www.ClinicalTrials.gov and www.pactr.org) with the aim of identify-
ing efficacious vaccines for implementation to manage the current epidemic and to control future EHF outbreaks. 
To date all of these vaccines currently in human trials target the EBOV envelope glycoprotein, GP. Results from 
experimental animal studies using these vaccines indicate that antibody and cellular immunity can be important 
for protection against EBOV8. Interim results from an ongoing phase 3 cluster randomized trial indicate that at 
least one of these candidates, based on vesicular stomatitis virus, may be highly efficacious and safe9. It remains 
to be seen whether the other vaccine candidates currently in human clinical trials will prove as protective against 
EBOV, and which immunological mechanisms are involved.
Cytomegalovirus (CMV) is a ubiquitous β -herpesvirus that has gained considerable interest for development 
as a vaccine vector platform10–13. Recent studies have shown CMV vectors to provide a unique, T-cell-biased 
‘effector’ (TEM) immune response11,14–16. TEM cells localize predominantly to extralymphoid mucosal sites and 
are functionally primed for immediate effector function17, making them particularly useful to target pathogens 
that replicate and spread rapidly within the host. Rhesus macaque CMV (RhCMV) vectors expressing simian 
immunodeficiency virus (SIV) antigens under the control of constitutively expressed heterologous promoters 
provide a level of protection against systemic SIV that is suggestive of complete immunological clearance of SIV 
from vaccinated animals in this macaque model of AIDS11,14,18 – something that has not previously been observed 
with any other vaccine platform.
We recently showed the ability of a single dose of a murine CMV (MCMV) expressing a CD8+ T cell 
epitope from the nucleoprotein (NP) of EBOV (MCMV/ZEBOV-NPCTL) to provide protection against 
lethal mouse-adapted EBOV challenge in the mouse model, which corresponded to induction of durable, 
EBOV-specific CD8+ T cell immunity15,16. Although lowered levels of CMV viremia during secondary infection 
indicate that some control over CMV replication is afforded by pre-existing host immunity19, the capacity for 
CMV re-infection remains remarkably unaffected20,21 even for low inoculums of CMV (~102 plaque forming 
units, pfu)21. This quality enables use of CMV-based vaccines in CMV-seropositive individuals, as well as the 
potential for serial re-use of CMV vectors encoding the same or different target antigen in the same individ-
ual11,14. CMVs are also highly species-specific, with the lack of CMV transmission between even closely related 
mammalian species22–24. The aim of the current study was to assess the protective efficacy of a RhCMV-based 
EBOV vaccine expressing full length EBOV GP (RhCMV/EBOV-GP) against a lethal EBOV challenge in CMV 
seropositive rhesus macaques, a translatable model for protection in humans25–27.
Results
Construction And Characterization Of RhCMV/EBOV-GP Vectors. GP was chosen as the EBOV 
immunogen, as it has been used highly successfully with other vaccine platforms8. Vectors were constructed as 
described in Fig. 1A11,14. Previously published RhCMV-based vectors have generally used constitutively expressed 
heterologous promoters for target antigen expression11,14,18. In RhCMV/EBOV-GP the full length codon-opti-
mized EBOV GP28 was instead placed under control of the endogenous RhCMV Rh112 (pp65b; pUL83b) pro-
moter, which is one of the most highly expressed endogenous RhCMV promoters. This resulted in deletion of the 
RhCMV Rh112 open-reading frame (ORF), an ORF known to be dispensable for secondary RhCMV infection 
and virus persistence29. The ability of a recombinant RhCMV deleted for Rh112 to induce T cell responses against 
its heterologous expressed SIV target antigen similarly shows that Rh112 is not required for induction of T cell 
immunity in CMV-immune NHPs29. Fig. 1B shows in vitro replication kinetics of two independent RhCMV/
EBOV-GP clones (2-8 and 6-1) in primary rhesus fibroblasts (RFs). Replication kinetics of RhCMV/EBOV-GP 
clones were delayed compared to parental WT virus (Fig. 1B), as we have observed previously for recombinant 
RhCMV expressing other heterologous antigens (unpublished results). GP expression was stable until at least 
passage 7 in RhCMV/EBOV-GP infected RFs (Fig. 1C). Similar to all herpesviruses, CMV genes differ in their 
time of expression during the virus replication cycle, being classified as immediate-early (IE), early (E) or late (L) 
genes. Expression kinetics revealed that GP was expressed in the late phase of RhCMV replication, consistent 
with its control by the L Rh112 promoter (Fig. 2A). The late expression of GP was confirmed by using the CMV 
DNA polymerase inhibitor, foscarnet, which blocks L gene expression (Fig. 2B).
RhCMV/EBOV-GP Vectors Induce A Robust Anti-EBOV-GP IgG Response. To determine efficacy of 
this new vaccine vector against lethal EBOV challenge, a group of 4 NHPs (rhesus macaques) was inoculated with 
RhCMV/EBOV-GP (Fig. 3A). Two additional control animals received the parental 68-1 BAC-derived RhCMV30. 
All NHPs were already RhCMV seropositive as a consequence of natural RhCMV infection (Fig. 3D). At day 
-112, the 4 animals allocated to the vaccine arm were inoculated with 1 × 107 pfu of RhCMV/EBOV-GP via the 
subcutaneous (s.c.) route. The 2 control animals received a comparable inoculation of 1 × 107 pfu of parental 68-1 
RhCMV. Animals were boosted in an identical fashion at day -28. NHPs were followed immunologically for T 
cell (Fig. 3B and Supp. Fig. 1) and EBOV-GP-specific IgG responses (Fig. 3C and Table 1). Previous studies using 
RhCMV vectors expressing SIV and human tuberculosis (TB) antigens under control of heterologous promoters, 
have shown immune responses against the target antigen to be shifted towards induction of cellular TEM-biased 
responses, with low or undetectable levels of antibodies11,14,18,31. We were therefore surprised to observe a rever-
sal of this immunological phenotype, with RhCMV/EBOV-GP vaccination being associated with substantial 
levels of EBOV-GP-specific antibodies (Fig. 3C). Consistent with the capacity for serial use of CMV vectors, 
the RhCMV/EBOV-GP boost at day -28 resulted in an increase in GP-specific antibodies (Fig. 3C). Only back-
ground levels of CD4+ or CD8+ T cells were present against the GP antigen, even following the day -28 ‘boost’. 
Although variable, T cell responses against antigens encoded by endogenous RhCMV genes (IE1 and Rh112) 
were observed in all animals. This antibody-biased immune response directed against the heterologous target 
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antigen (GP) is a phenotype not seen previously for any RhCMV-based vaccine11,14, or for other recombinant 
primate herpesvirus-based vectors32.
RhCMV/EBOV-GP Vectors Protect Against Lethal EBOV challenge. To assess whether immunity 
induced by RhCMV/EBOV-GP protected animals from lethal EHF, the 6 NHPs were challenged with a lethal dose 
of EBOV at day 0. NHPs were monitored twice daily, and physical exams and blood draws were conducted on 
day 0, 4, 7, 10, 14, 21, 28, and 35 (Fig. 3A). Clinical findings are presented in Fig. 4A–G. Three of the 4 RhCMV/
EBOV-GP vaccinated NHPs survived EBOV challenge (NHP#4, NHP#5 and NHP#6) indicating that vaccination 
had induced a protective immune response against EBOV. Two of the 3 protected animals were febrile (>1 °C 
above baseline) at day 4, but all animals returned to normal body temperature by day 10. Transient low-level 
viremia was observed in one animal (NHP#4) at a single time point (day 7), but viremia was undetectable in the 
remaining animals (NHP#5 and NHP#6) (Fig. 4C). One vaccinated animal (NHP#4) developed mild signs of dis-
ease, but survived. The 2 animals (NHP#1 and NHP#2), which received control vaccine were both febrile at day 4, 
and then rapidly developed EHF, reaching a predetermined clinical humane endpoint by days 6 and 7. A single 
animal from the vaccinated group (NHP#3) showed disease progression similar to controls, and was euthanized 
on day 6. Despite similar disease progression, the kinetics of viremia in NHP#3 were delayed, being 1- and 2-logs 
Figure 1. Construction and characterization of RhCMV vectors engineered to express EBOV GP 
(designated RhCMV/EBOV-GP). (A) Schematic representation of RhCMV/EBOV-GP. Codon-optimized 
full-length EBOV GP was inserted within the RhCMV genome (68.1) to replace the endogenous Rh112 (pp65b) 
ORF. This approach places GP under the control of the endogenous RhCMV Rh112 promoter. (B) Multi-step 
growth analysis of RhCMV/EBOV-GP. RFs were infected at a multiplicity of infection (MOI) of 0.01 with 
either RhCMV/WT, RhCMV/EBOV-GP[2–8] or RhCMV/EBOV-GP[6–1]. Supernatant was collected at days 
indicated post infection and titered using a TCID50 assay. The assay was performed in triplicate and standard 
deviation is shown. (C) Western analysis of RhCMV/EBOV-GP infected RF cell lysates showing stable expression 
of EBOV GP until at least passage 7. The EBOV GP was tagged at the carboxyl terminus with a V5 epitope to 
facilitate detection, and V5 epitope tag-specific monoclonal antibody (mAb) or a GP EBOV-specific mAb were 
used for detection. V5 activity was observed against 3 bands as predicted [26kDa GP2, 110kDa preGPer (full 
length endoplasmic reticulum form; not shown) and 160kDa preGP (full length Golgi form; not shown)]55. The 
GP-specific mAb was used to detect GP1 (140kDa) as the V5 tag is localized at the carboxyl-terminus of GP. 
Endogenous RhCMV IE-1 was used as an infection level control.
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lower than control animals at day 4 (Fig. 4C), suggesting that RhCMV/EBOV-GP vaccination may have provided 
some low, partial level of protection in this animal. By day 6, EBOV levels in blood and tissues were comparable 
in NHP#3 and controls (data not shown). At this time, all 3 unprotected animals had severe thrombocytopenia 
and highly elevated levels of AST and ALT. Presence of macular cutaneous rash/petechiae over multiple areas in 
all of these animals was consistent with EHF. No rash was observed in any of the 3 protected RhCMV/EBOV-GP 
vaccinated animals.
Protection Against Lethal EBOV Challenge Appears To Correlate With Anti-EBOV-GP IgG 
Levels. Given that the immunological phenotype for RhCMV-based vectors is normally heavily biased 
towards cellular TEM memory with minimal antibody production11,14,32, the induction of a substantial anti-GP 
antibody response by RhCMV/EBOV-GP with an absence of detectable GP-specific T cells was unexpected. 
Although the present study was not powered for identification of the mechanism of protection for this vaccine, 
survival of the RhCMV/EBOV-GP immunized animals appeared to correlate with total EBOV GP-specific IgG 
level, as the single non-protected vaccinated animal (NHP#3) showed the lowest level of total GP-specific IgG 
(Fig. 3C). Recent cellular depletion studies in NHPs have confirmed that antibody rather than cellular GP-specific 
immune responses are of primary importance for recombinant vesicular stomatitis virus (rVSV)-EBOV-mediated 
protection33. The rapid decrease of anti-GP antibodies that we observed here in all the vaccinated animals at day 4 
post challenge (Fig. 3C) has been seen before in EBOV immune animals following EBOV challenge34. Given the 
speed of decline (within 4 days of challenge) and the absence of leukocytopenia (Fig. 4D), this drop in antibody 
levels is likely caused by antibody-mediated consumption of EBOV. The decrease of GP-antibodies to below 
baseline levels in only the single vaccinated animal that died from EBOV disease is also persuasive of protection 
being afforded by a predominantly antibody-mediated mechanism. Neutralizing antibody titers were absent in 
vaccinated animals before challenge (day 0) and remained very low in protected animals after challenge (day 35) 
(Table 1), consistent with that observed for rVSV-EBOV vaccinated animals35. Additional studies powered to 
identify correlates of protection, as well as the use of depletion will be necessary to definitively determine the 
mechanism of RhCMV/EBOV-GP mediated protection.
Discussion
Even though distinct immunological mechanisms appear to be at play, the present study shows that the protec-
tive immunity of CMV vectors initially suggested by mouse studies15,16 translates into protective efficacy using 
Figure 2. RhCMV/EBOV-GP expresses GP at late times of replication. (A) Western blot analysis of RhCMV/
EBOV-GP in RFs showing EBOV GP expression at L times of replication. RFs were infected at a MOI of 0.03 
with either RhCMV/WT, RhCMV/EBOV-GP[2–8] or RhCMV/EBOV-GP[6–1]. Cell lysates were collected at 
days indicated post infection and analyzed by western blot. Accumulation of GP was compared to accumulation 
of viral proteins known to be expressed with IE (IE-1), E (pRh70) and L (pRh112) kinetics. (B) Western blot 
analysis showing GP expression with L gene kinetics. RFs were infected at a MOI of 0.03 with either RhCMV/
WT, RhCMV/EBOV-GP[2–8] or RhCMV/EBOV-GP[6–1] and treated with the CMV DNA polymerase 
inhibitor, foscarnet (200 μ g/ml). Cell lysates were collected at indicated days post infection and analyzed for 
expression of indicated proteins. Absence of Rh112 and EBOV GP protein in the presence of foscarnet confirms 
expression of GP at L times of replication.
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RhCMV-based vectors in the NHP EBOV challenge model. This study suggests a potential for development of 
CMV as prophylactic vaccine for ebolavirus in humans possibly using attenuated or replication-deficient CMVs. 
The relative contribution of antibodies compared to cellular immunity for protection against ebolavirus remains 
incompletely resolved36. In NHP experimental studies, rAd-based and rVSV-based ebolavirus vaccines appear 
to differ in their modes of protection – the former has been suggested to be primarily associated with cellular 
immunity37–39, whilst rVSV appears to be more antibody-mediated33. However, for both platforms total anti-GP 
antibody level correlates highly with survival from EBOV challenge in NHPs40, and total anti-GP antibody level 
Figure 3. RhCMV/EBOV-GP induces high levels of EBOV GP-specific antibodies with absence of GP-
directed T cell responses in NHPs. (A) Schematic showing timeline of ‘vaccine’ and ‘challenge’ phases and 
sampling schedule. (B) Time course of CD4+ and CD8+ T cell responses against IE-1, pRh112 (pp65b) and GP. 
T cells were analyzed by ICS following incubation with overlapping peptide pools in the presence of brefeldin 
(A). Levels of responding cells (TNFα and IFNγ double-positive) in individual NHPs are shown at indicated 
time points. T cell responses against endogenous RhCMV antigens (IE-1 and Rh112) were observed in all 
animals, while no responses against GP were detected at any time. (C) Time course of antibody responses 
against EBOV GP. Total EBOV GP-specific IgG levels were measured by ELISA at indicated time points. 
(D) RhCMV-specific antibody levels prior to vaccination. Presence of RhCMV-specific antibodies prior 
to vaccination (pre-bleed samples) indicates that all NHPs were RhCMV seropositive as a result of natural 
RhCMV infection at the time of initial vaccination.
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has also been used as a primary immunological read-out for recent human clinical EBOV vaccine trials9,41,42. In 
the present study, the absence of substantial neutralization capacity of the EBOV antibodies induced by RhCMV/
EBOV-GP implicates antibody effector mechanisms other than direct neutralization of virus infection in EBOV 
control, such as antibody-dependent cellular cytotoxicity (ADCC) or complement.
Vaccination with RhCMV/EBOV-GP induced substantial levels of EBOV-GP specific antibodies, but failed to 
induce the typical TEM biased antigen specific T cell responses observed in other RhCMV-based vaccine vector 
studies11,14. Although one recent study in mice using a murine CMV-based vector has shown a similar pheno-
type43, this immunological shift towards antibodies has never been observed in macaques using RhCMV vectors, 
where responses are heavily T cell-biased with low antibodies induced against the heterologous target antigen11,14. 
The established capacity of rAd-expressed GP to induce GP-specific T cell responses44 indicates that the GP target 
protein does contain functional T cell epitopes. We hypothesize that the antibody-biased response phenotype 
seen in our study may result from expression of the GP target antigen being placed under control of the L Rh112 
promoter. Expression at L times coincides with the expression of multiple CMV-encoded immunoevasins that 
downregulate MHC expression45. In our current model, the inability to present the heterologous target antigen 
to T cells via the canonical MHC pathway would shift immune responses away from cellular towards humoral 
immunity.
The high levels of GP antibodies induced by RhCMV/EBOV-GP and their ability to undergo IgG class switch-
ing indicates the presence of sufficient CD4+ T cell helper function. Given that CD4+ T cell responses against 
GP were below the level of detection in our study, this raises the possibility that CD4+ T cells directed against 
endogenous CMV proteins are functioning in trans to support the GP antibody response. This immune enhance-
ment phenomenon has been observed in other systems, in particular during co-expression of the high-affinity 
Pan HLA-DR reactive epitope (PADRE) to supply CD4+ T cell help in trans to enhance immunogenicity against 
co-expressed target proteins46–48. The ability to modulate the adaptive immune response raises the possibility for 
rational design of vaccines that can direct the pathogen-specific immune response towards either antibody pro-
duction with diminished T cell responses (by use of a promoter expressed at L times), or towards T cell responses 
with diminished antibody responses (by use of a promoter expressed at IE/E times). Using different kinetic classes 
of promoters to drive target antigen expression, either within distinct vaccines or within the same vaccine con-
struct, would enable a balanced antibody and T cell response to be achieved. This raises the possibility of being 
able to recruit both arms of the immune response together against ebolavirus infection in a single CMV vaccine 
by differential promoter usage. The capacity to modulate the adaptive immune response may also have application 
to non-infectious disease, for example in preventing induction of meningoencephalitic T cell responses during 
antibody targeting of β -amyloid – a promising immunotherapeutic approach in preclinical and clinical trials as 
treatment for Alzheimer’s disease49.
Given its high-species specificity and ability to spread, even between CMV-seropositive individuals20,50,51, 
CMV may also be suited towards development as a ‘self-disseminating’ vaccine to target wildlife populations 
involved in EBOV zoonotic transmission (bats and great apes)52. Great apes (chimpanzees and western lowland 
gorillas) are one source of zoonotic ebolavirus transmission during human ebolavirus outbreaks, and are thought 
to represent a ‘dead-end’ host similar to humans53. Serological surveys and likely involvement of fruit bats in 
some human EBOV oubreaks similarly implicates bat species, most likely as a virus reservoir, in EBOV zoonotic 
transmission53,54. Use of a CMV-based ‘self-disseminating’ EBOV vaccine is one strategy that has been proposed 
to overcome the significant hurdles to providing protective EBOV-specific immunity in these inaccessible wildlife 
populations15,16,52. The present study used direct inoculation of animals for RhCMV/EBOV-GP vaccine adminis-
tration, and immunity following animal-to-animal spread of the vector will now need to be investigated.
Methods
Animal Ethics and Biosafety Statement. All macaque work was performed in strict accordance with the 
recommendations described in the Guide for the Care and Use of Laboratory Animals of the National Institute 
of Health, the Office of Animal Welfare and the United States Department of Agriculture. Animal procedures 
were carried out under anesthesia by trained personnel under the supervision of veterinary staff and all efforts 
Animal ID Pre-challenge (D0) Post-challenge (D35)
PRNT50
NHP#1 ≤ 40 ≤ 40
NHP#2 ≤ 40 ≤ 40
NHP#3 ≤ 40 ≤ 40
NHP#4 ≤ 40 ≤ 40
NHP#5 ≤ 40 ≤ 40
NHP#6 ≤ 40 ≤ 40
Negative control ≤ 40
Positive control 160
Table 1. RhCMV/EBOV-GP induces low levels of EBOV neutralizing antibodies. Neutralizing antibody 
titers were measured in vaccinated animals before challenge (day 0) and in protected animals after challenge 
(day 35). Shown is the plaque reduction neutralization test 50 (PRNT50) value, which is the highest plasma 
dilution that results in ≤ 50% of input plaque count (in absence of plasma).
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were made to promote the welfare and to minimize animal suffering in accordance with the “Weatherall report 
for the use of non-human primates” recommendations. Animals were housed in adjoining individual primate 
cages allowing social interactions, under controlled conditions of humidity, temperature and light (12-hour 
light/12-hour dark cycles). Food and water were available ad libitum. Animals were monitored at least twice daily 
(pre- and post-infection) and fed commercial monkey chow, treats and fruit twice daily by trained personnel. 
Environmental enrichment consisted of commercial toys. Humane endpoint criteria, specified and approved by 
the Institutional Animal Care and Use Committee (IACUC), were applied to determine when animals should be 
humanely euthanized. All infectious animal work was performed in the maximum containment laboratory at the 
Rocky Mountain Laboratories (RML), Division of Intramural Research (DIR), National Institute of Allergy and 
Infectious Diseases (NIAID), National Institutes of Health (NIH), Montana, USA applying standard operating 
protocols approved by the Institutional Biosafety Committee (IBC).
Vaccine Vectors. We constructed RhCMV/EBOV-GP essentially as previously described11, by using E/T 
linear recombination to manipulate the parental RhCMV strain 68-1 genome cloned within a bacterial artificial 
chromosome (BAC)30. A codon-optimized version of GP (optZGP) from EBOV (Mayinga strain 76; Accession 
number AF086833) was used as the target antigen28. The optZGP open reading frame (ORF) was inserted within 
the RhCMV genome to replace the non-essential endogenous RhCMV Rh112 (pp65b) ORF (nucleotide posi-
tions 111,240 to 112,868 of RhCMV; see schematic Fig. 1A)56. This strategy places optZGP under control of the 
Rh112 promoter. The optZGP was epitope-tagged at the carboxy terminus with a V5 epitope. RhCMV/EBOV-GP 
BAC clones were analyzed in vitro as previously described (data not shown)11. Recombinant RhCMV/EBOV-GP 
viruses were reconstituted by transfection of BAC DNA into RFs30. Stability of optZGP expression in RhCMV/
EBOV-GP vectors over at least 7 passages was confirmed by western analysis of infected cell lysates using mon-
oclonal antibodies directed against EBOV GP1 and against the V5 epitope tag (Invitrogen) (Fig. 1C). Multi-step 
growth analysis of the RhCMV/EBOV-GP was performed as described11.
Figure 4. Clinical parameters in RhCMV/WT and RhCMV/EBOV-GP vaccinated animals. Changes in 
various clinical parameters were measured over the duration of the study. (A) Kaplan-Meier survival curves,  
(B) body temperature, (C) viremia, (D) white blood cell (WBC), and (E) platelet counts, and levels of (F) aspartate 
aminotransferase (AST) and (G) alanine aminotransferase (ALT).
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Challenge Virus. EBOV strain Mayinga (passage 5) was propagated on Vero E6 cells (mycoplasma negative), 
titrated on these cells and stored in liquid nitrogen. Deep sequencing confirmed the “7U phenotype” for this 
EBOV strain.
SDS-PAGE and western blotting. RFs infected at a multiplicity of infection (MOI) of 0.03 with either 
RhCMV/WT, RhCMV/EBOV-GP[2–8] or RhCMV/EBOV-GP[6–1] were solubilized in 1X Lamelli’s sample 
buffer, homogenized using QiaShredders (Qiagen), heated to 100 °C for 10 min, loaded onto 12% polyacrylamide 
gels and run in Tris-glycine buffer. Proteins were transferred to PVDF membranes (Bio-Rad) and blocked with 
5% skimmed milk powder in Tris-buffered saline with 0.01% Tween-20 (TBST) overnight at 4 °C. Primary and 
secondary antibodies (HRP labeled; Bio-Rad) were applied at indicated dilutions: anti-V5 (1:1,500), anti-GP1 
(1:10,000), anti-Rh112 (pp65b) (1:100), anti-Rh156 (IE-1) (1:500), anti-Rh70 (UL44) (1:2), anti-p38 (Santa Cruz 
Biotechnology, Inc.) (1:500), and secondary anti-mouse HRP (1:2,000) and anti-rabbit HRP (1:2,000). All anti-
bodies were incubated for 1 hour at room temperature followed by three 5 minute washes with TBST. Membranes 
were developed using either ECL Western blotting substrate (Thermo Scientific) or SuperSignal West Femto 
substrate (Thermo Scientific), and imaged using a UVP ChemiDoc-It2 imaging system.
Study design. Six adult male and female NHPs of Indian genetic background were used for the study. 
Animals were confirmed to be RhCMV seropositive by ELISA before initiation of the study (resulting from nat-
ural RhCMV infection) (Fig. 3D). Animals were filovirus-naïve and were also free of cercopithicine herpesvirus 
1, simian T-lymphotropic virus type 1, D-type simian retrovirus and simian immunodeficiency virus. Animals 
were assigned to either RhCMV/EBOV-GP vaccine (n = 4) or parental wild-type RhCMV/WT control (n = 2) 
groups with an aim of achieving a relatively equal distribution based on sex and age. On day -112, the vaccine 
group received a single s.c. bolus of a mixture of two independent clones of the RhCMV/EBOV-GP construct 
(5 × 106 pfu/construct). RhCMV/EBOV-GP and RhCMV/WT were administered subcutaneously as this has 
been the route used for inoculation of rhesus macaques in all earlier studies using RhCMV-based vectors (in this 
case, expressing SIV antigens11,14,18). The RhCMV/WT control group received a single 1  ×  107 pfu s.c. inocula-
tion of parental RhCMV/WT (clone 68-1)30. Animals were boosted with RhCMV/EBOV-GP clones or RhCMV/
WT at week 12 (day -28). Blood samples were collected at times indicated over the pre-challenge 112 day period 
(vaccination phase) (Fig. 3A). Peripheral blood mononuclear cells (PBMCs) and plasma were prepared from 
blood by centrifugation on a histopaque gradient (Sigma) and assayed as detailed below. On day 0 (112 days 
post-vaccination), all animals were challenged with a lethal dose of 1,000 focus forming units of EBOV (strain 
Mayinga) by intramuscular administration at two anatomical locations (left and right caudal thigh). Animals 
were monitored twice daily for clinical signs of disease. Disease progression was assessed based on pre-established 
endpoints, and animals were humanely euthanized when clinical signs indicated onset of terminal disease. Blood 
samples were collected at times indicated (Fig. 3A) over the 35 day post-challenge period.
Hematology and serum chemistry. A HemaVet® 950FS laser-based hematology analyzer (Drew 
Scientific) was used to analyze the following blood parameters in 20 μ l volumes of EDTA-treated blood: i) total 
white blood cell count, ii) lymphocyte, platelet, reticulocyte and red blood cell counts, iii) hemoglobin, iv) hema-
tocrit values, and v) mean corpuscular volume and hemoglobin concentrations. Serum chemistry was analyzed 
using a Piccolo Xpress Chemistry Analyzer using Piccolo General Chemistry 13 Panel discs (Abaxis).
Viral loads. Levels of infectious EBOV were measured by using standard virus titration33, followed by cal-
culation of 50% tissue culture infectious dose (TCID50) using the method of Reed and Muench57. Tissues were 
homogenized prior to analysis.
Intracellular cytokine staining analysis of T cells. Frequencies of CD4+ and CD8+ T cells directed 
against the EBOV (Mayinga) GP target antigen, as well as RhCMV IE-1 and Rh112 proteins were determined 
during the vaccine phase by intracellular cytokine staining (ICS) as previously described33. For stimulation, 
PBMC (1–2 × 106 cells/well) were incubated in vitro with peptide pools (1 μ g/ml final concentration) of over-
lapping peptides (11-mer with 5 amino acid overlap) representing each of the target ORFs. Incubation without 
antigen served as a background control. After 1 hour, brefeldin A (10 μ g/ml) was added and cells were incubated 
for an additional 14 hours. Cells were surface stained using the following mAbs in indicated combinations: CD3, 
CD4 (eBioscience) and CD8β (Beckman Coulter). Cells were fixed and permeabilized according to manufactur-
er’s recommendations (BioLegend) prior to staining for intracellular staining using mAbs against Ki67 (BD) and 
IFNγ and TNFα . Polychromatic flow cytometric analysis was performed on a LSR II (BD Biosciences), and data 
was analyzed by using FlowJo software (version 10; Tree Star, Inc.). Response frequencies were determined by 
subtracting background and then averaging background subtracted responses.
Enzyme-linked immunosorbent assay (ELISA). Total IgG antibody responses to RhCMV/EBOV-GP 
were measured by ELISA using either EBOV GPΔ TM or RhCMV/WT infected cell lysate as a source of antigen, 
as previously described58. The end-point dilution titer (using a 4-fold dilution series) is shown. Post-challenge 
plasma samples were inactivated by γ -irradiation (5Mrad) before removal from BSL-4 containment under stand-
ard RML operating procedures as approved by the RML Institutional Biosafety Committee (IBC). Samples were 
deemed positive for EBOV GP-specific IgG when the OD value was higher than the mean plus 3 standard devia-
tions of negative (RhCMV WT) sera59.
Neutralization assay. Neutralizing antibody titers were determined by performing focus reduction neutral-
ization titration assays. Briefly, Vero E6 cells (mycoplasma negative) were seeded into 96-well plates to generate 
a confluent monolayer on the day of infection. Two-fold serum dilutions were prepared in triplicate in plain 
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DMEM and 25 μ l were incubated with 200 pfu EBOV (strain Mayinga) in a total volume of 50 μ l. After 60 min 
at 37 °C the media was removed from cells, the serum-virus mixture was added and samples were incubated for 
60 min at 37 °C. The mixture was then removed and 100 μ l of 1.2% carboxymethyl cellulose in MEM (2% FBS) 
was added per well followed by incubation for 4 days at 37 °C. Cells were fixed in 10% neutral buffered formalin 
and removed from the maximum containment laboratory according to approved standard operating procedures 
(SOPs). Foci based either on GFP or staining using an anti-EBOV VP40 polyclonal rabbit serum and a secondary 
anti-rabbit FITC antibody (Sigma). Foci were counted and the neutralizing activity was determined as percent 
reduction of EBOV infection compared to control infected cells without plasma. Negative control: EBOV naïve 
rhesus macaque plasma. Positive control: NHP plasma of EBOV survivor.
Statistical analysis. Kaplan-Meier survival curves were performed to visualize survival rates between 
groups in EBOV challenge studies. Analysis was performed using Prism GraphPad Software (Version 5.0d).
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